5.59
0.00 (0.00%)
0.00 (0.00%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Adamas Pharmaceuticals Inc | ADMS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.01 | -0.18% | 5.59 | 5.56 | 5.75 | 5.62 | 5.60 | 20:00:00 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 5.35 | 6.05 | 0.70 | 11.57% | - | 1 |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 2,491 | 314,819 | $ 5.64 | $ 1,775,723 | 467,511 | 3.35 - 12.57 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:16:35 | priorref | 600 | $ 5.59 | USD |
Adamas Pharmaceuticals Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 155.72M | 27.86M | $ -131.00M | -4.88 | - | 26.98M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | 2.00 | 3.20% |
Adamas Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ADMS Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 5.67 | 6.15 | 5.475 | 5.74 | 286,825 | -0.08 | -1.41% |
| 1 Month | 6.02 | 6.15 | 4.95 | 5.57 | 243,553 | -0.43 | -7.14% |
| 3 Months | 5.52 | 7.45 | 3.47 | 4.94 | 655,559 | 0.07 | 1.27% |
| 6 Months | 6.50 | 7.78 | 3.35 | 5.16 | 586,045 | -0.91 | -14.0% |
| 1 Year | 10.69 | 12.57 | 3.35 | 5.89 | 520,284 | -5.10 | -47.71% |
| 3 Years | 17.44 | 44.00 | 3.35 | 18.39 | 608,909 | -11.85 | -67.95% |
| 5 Years | 17.40 | 44.00 | 3.35 | 18.49 | 447,478 | -11.81 | -67.87% |
Adamas Pharmaceuticals Description
| Adamas Pharmaceuticals Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. It operates in one reportable segment: the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The company generates its revenues primarily from the United States. |
